C

    Clearmind Medicine Inc. Common Shares (CMND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.76
    -0.05 (-2.76%)

    Market Cap: $2.61M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Apr 26
    		$-6.78N/AN/ABeat-4137.5%
    Jan 26
    		$-33.17N/AN/ABeat-13720.5%
    Oct 25
    		$-5.03N/AN/ABeat+93.9%
    Jul 25
    		$-9.84N/AN/ABeat+95.8%
    Apr 25
    		$-0.16N/AN/ABeat+99.9%
    Jan 25
    		$-0.24N/AN/ABeat+99.9%
    Oct 24
    		$-82.97N/AN/ABeat+98.2%
    Jul 24
    		$-235.28N/AN/ABeat+75.8%
    Apr 24
    		$-111.67N/AN/ABeat+98.3%
    Jan 24
    		$-360.55N/AN/ABeat+96.2%
    Oct 23
    		$-4575.59N/AN/ABeat+68.4%
    Jul 23
    		$-973.68N/AN/ABeat+93.2%
    Apr 23
    		$-6649.15N/AN/ABeat+71.1%
    Jan 23
    		$-9524.72N/AN/ABeat+39.8%
    Oct 22
    		$-14495.60N/AN/ABeat+24.9%
    Jul 22
    		$-14305.95N/AN/ABeat-
    Apr 22
    		$-22967.79N/AN/ABeat-
    Jan 22
    		$-15824.06N/AN/ABeat-
    Oct 21
    		$-19307.35N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.03EV/EBITDA-0.79x
    Price/FCF-0.08xFCF Yield-1272.52%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-114.60%ROIC-64.14%
    Financial Health
    Debt/Equity0.00xInterest Coverage-311.25x
    Current Ratio4.79xQuick Ratio4.79x
    Trading Statistics
    Beta-1.18Avg Volume126.83K
    52-Week High$524.0052-Week Low$1.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.79
    SMA 20$1.75
    SMA 50$1.95
    SMA 200$16.90
    EMA 10$1.76
    EMA 20$1.78
    EMA 50$2.46
    EMA 200$62.85

    MACD

    Line: -0.06Signal: -0.09Hist: 0.03

    ADX

    ADX: 14.0+DI: 24.1-DI: 18.2

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down12.0
    PSAR$2.26

    Bollinger Bands

    Upper Band$1.96
    Lower Band$1.54
    %B Position2380%(Upper)
    Band Width0.53

    RSI (14-Day)

    Neutral
    46.1

    Momentum Oscillators

    Stoch %K29.0
    Stoch %D25.7
    Williams %R-71.4
    ROC (10d)-5.4%
    Momentum-0.10
    CCI (20d)18.4
    MFI (14d)78.2

    Volatility Measures

    ATR (14d)$0.18(10.5%)
    StdDev (20d)0.10
    Hist Vol73.8%(High)

    Volume Flow

    VWAP$1.78
    OBV97.5M
    AD Line3354.2B
    CMF (20d)-0.040

    Volume Metrics

    Avg Vol (20d)126.8K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.80

    Pivot Points

    R3$1.96
    R2$1.90
    R1$1.86
    Pivot Point$1.80
    S1$1.76
    S2$1.70
    S3$1.66

    Advanced Oscillators

    TSI-10.77
    Ultimate Osc41.9
    KST-9.04

    Financial Data

    QuarterApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$13,901$13,318$12,836$12,522$11,978$12,031$11,511$15,196$15,730$8,632$4,011$17,722
    Gross Profit$-13,901$-13,318$-12,836$-12,522$-11,978$-12,031$-11,511$-15,196$-15,730$-8,632$-4,011$-17,722
    Operating Expenses$1.56M$3.64M$1.44M$1.40M$1.30M$1.48M$1.57M$1.46M$1.29M$1.38M$1.71M$1.07M
    R&D$644,036$637,344$417,382$720,288$449,521$458,428$483,729$343,251$320,114$224,753$374,561$261,102
    SG&A$924,502$3.02M$997,661$948,742$855,124$1.03M$1.06M$1.13M$980,549$1.16M$943,656$628,360
    Operating Income$-1,571,209$-3,657,688$-1,456,123$-1,407,765$-1,307,958$-1,495,362$-1,586,178$-1,471,805$-1,302,933$-1,384,214N/A$-1,090,967
    Interest Income$42,025$64,649$24,659$32,593$41,648$34,008$91,669$85,024$33,955$60,576$60,576$17,307
    Interest Expense$4,233$4,103$6,238$9,192$7,873$8,710$36,160$61,408$0$2,926$5,999$0
    Income Before Tax$-2,044,341$-3,848,280$-685,584$-1,305,335$-763,840$-1,031,725$-787,622$-2,052,104$-871,079$-1,166,488$-4,052,911$-575,534
    Income Tax Expense$3,311$3,957$0$8,257$20,673$39,313$97,119$42,605$36,739$201,531$11,337$-6,559
    Net Income$-2,047,653$-3,852,238$-687,777$-1,313,593$-784,513$-1,071,039$-884,742$-2,094,710$-907,818$-1,368,021N/A$-568,974
    EBITDA$-1,557,308$-3,830,859$-672,749$-1,283,618N/A$-1,010,983$-1,179,886$-2,036,909$-855,345$-1,157,852N/A$-557,806
    EBIT$-1,571,209$-3,844,177$-685,585$-1,296,140N/A$-1,023,014$-1,191,397$-2,052,105$-871,075$-1,166,484N/A$-575,528
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CMND

    News

    New MDMA combo targets PTSD, anxiety at Clearmind (NASDAQ: CMND)

    Clearmind Medicine Inc. (NASDAQ: CMND) announced the U.S. publication of a patent application for a novel combination of MDMA and N-acylethanolamines, such as PEA, aimed at treating PTSD, anxiety, and eating disorders. This development, stemming from a collaboration with NeuroThera Labs Inc., aligns with the FDA's recent guidance on psychedelic drug development, explicitly including MDMA. The company highlights that this combination may enhance MDMA's therapeutic potency, reduce dosing, mitigate side effects, and broaden its therapeutic window.

    Stock Titan•8/24/26•
    Bullish

    SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

    SciSparc's subsidiary NeuroThera Labs, in collaboration with Clearmind Medicine, has advanced its intellectual property with the publication of a U.S. patent application for a novel combination of MDMA and N-acylethanolamines (like PEA) for treating PTSD, anxiety, and eating disorders. This development aligns with increasing U.S. federal support for psychedelic medicines, highlighted by recent FDA guidance on clinical investigations of psychedelic drugs, including MDMA. The collaboration aims to optimize MDMA's therapeutic effects, potentially reducing side effects and required dosing.

    The Manila Times•8/24/26•
    Bullish

    NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

    NeuroThera Labs Inc. and Clearmind Medicine Inc. announced the publication of a U.S. patent application for a novel combination of MDMA and N-acylethanolamines, such as PEA, for treating PTSD, anxiety, and eating disorders. This development aligns with increasing U.S. federal support for psychedelic medicine, including recent FDA guidance on psychedelic drug development. The collaboration aims to leverage NeuroThera's PEA technology to enhance MDMA's therapeutic potential and broaden its application.

    TheNewswire•8/24/26•
    Bullish

    Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder

    Clearmind Medicine (Nasdaq: CMND) is advancing its CMND-100 clinical trial for Alcohol Use Disorder (AUD) to Parts B and C after successfully meeting the primary safety endpoint in Part A. Part B will evaluate CMND-100 in patients with moderate to severe AUD, while Part C will further characterize safety in healthy participants. This progression marks a significant milestone, allowing the company to test its non-hallucinogenic neuroplastogen-derived therapeutic directly in the target patient population.

    Stock Titan•8/13/26•
    Bullish

    Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder

    Clearmind Medicine has received approval from its Independent Data and Safety Monitoring Board (DSMB) to advance its CMND-100 clinical trial for Alcohol Use Disorder (AUD). Following successful completion of Part A, which confirmed safety and tolerability in healthy participants, the trial will now proceed to Parts B and C, evaluating CMND-100 in patients with moderate to severe AUD and further assessing safety in healthy individuals. CMND-100 is a non-hallucinogenic neuroplastogen developed to address addiction by promoting neuroplasticity.

    Quiver Quantitative•8/13/26•
    Bullish

    Frequently Asked Questions About CMND

    Does CMND pay dividends?
    Clearmind Medicine Inc. Common Shares (CMND) does not currently pay a regular dividend.
    What is CMND's market cap?
    Clearmind Medicine Inc. Common Shares (CMND) has a market capitalization of $2.61M with a current stock price of $1.76.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In